Buyout talks come to a close with the acquisition of InVentiv Health
Date of publication: July 23, 2010
InVentiv Health, the pharmaceutical and biotechnology outsourcing solution provider has been acquired for a total of $1.1billion in cash by the private equity firm Thomas H Lee Partners. See this illustrated on our 2010 M&A Scorecard
This announcement follows months of negotiations and the figure equates to $26 per share at a 52% premium over the $17.15 closing stock price as of 25 March.
This acquisition also follows the recent acquisition by InVentiv Health December 2009 for specialized pharmaceutical risk management company ParagonRx and the marketing agreement with Medidata Solutions.
Together these deals will ensure that InVentiv continues to provide integrated programs to the pharmaceutical and biotech industry across the product lifestyle.
Tim Martin
July 2010